So big but so what? Innovent’s license deal fails to excite investors
The Chinese biotech is selling some cancer drug rights to a Japanese pharma giant for up to $11.4 billion, pocketing a big downpayment, so why did its stock price fall?…
FAST NEWS: Innovent Bio’s loss narrows on strong sales growth
The latest: Biotech company Innovent Biologics Inc. (1801.HK) announced Wednesday its annual net loss last year narrowed 52.8% year-over-year to 1.03 billion yuan ($143 million), while its non-GAAP net narrowed by an even…
Henlius finds elixir in first profits, scraps A-share IPO
The drug maker said last week it will halt plans for a second listing on China’s STAR Market, the same day it announced its first-ever interim profit since its 2019…
FAST NEWS: CStone drug approved for treatment of advanced non-small cell lung cancer
The Latest: Drug maker CStone Pharmaceuticals (2616.HK) announced on Tuesday its Pralsetinib, also known by the brand name Gavreto, was approved by China’s drug regulator as a first-line treatment for…
Drug Startups Eye Quicker Profits Under China’s New Fast-Track Approvals
Key changes designed to bring cutting-edge drugs more quickly to market have yet to ignite significant rally for money-losing startups Key takeaways: New fast-track approval system could bring cutting-edge drugs…
Biosimilar Specialist Henlius Takes Off. Now Comes the Hard Part
Fosun Pharma-backed company posts huge revenue jump in the second half of last year, as it boosts production and signs more global licensing deals to stay ahead of competition Key…
Recent Articles
RELATED ARTICLES
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK -
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
InnoCare licensing deal flops due to lack of upfront cash
9969.HK 688428.SHG
-
XtalPi scores landmark deal for AI drug discovery
2228.HK
-
RemeGen’s $4.2 billion licensing deal falls flat with investors
9995.HK 688331.SHG
-
HBM notches up another mega deal but is the model sustainable?
2142.HK
- Obesity drug maker Sciwind targets IPO, with heavyweight backers
